BERRY, Leanne,PHILLIPS, Gail Lewis,SLIWKOWSKI, Mark X.
申请号：
AU2017200047
公开号：
AU2017200047A1
申请日:
2017.01.05
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2017200047A120170202.pdf#####ABSTRACT Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 8556883_1 (GHMatters) P85021.AU.2i /27 SKBR3 Proliferation - 3 Days 1.2 1 trastuzumab 0.8 C 0.6 ca Combo: T-DM1 trastuzumab 0 0.4 0.2 T-DM1 0 0.25x 0.5x 1x 2x 4x Bx 16x IC50 Multiple Figure 1 BT474-EEI Proliferation - 3 Days 1.2 Q trastuzumab 1 - 0.8 Combo: T-DM1 + trastuzumab -2 0.6 0T-DM1 0.4S 0.20 0 z 0 0.125x 0.25x 0.5x 1x 2x 4x 8x IC50 Multiple Figure 2
